Technical Analysis for GNHAY - Vifor Pharma Ag ADR

Grade Last Price % Change Price Change
grade A 31.45 25.30% 6.3500
GNHAY closed up 25.3 percent on Wednesday, October 16, 2019, on 4 percent of normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up
See historical GNHAY trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week High Strength 0.00%
Gapped Up Strength 0.00%
Hot IPO Pullback Bullish Swing Setup 25.30%
Narrow Range Bar Range Contraction 25.30%
Gapped Down Weakness 25.30%
Outside Day Range Expansion 24.80%
Volume Surge Other 24.55%
Gapped Up Strength 24.55%
Older signals for GNHAY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Vifor Pharma AG develops, manufactures, and distributes pharmaceutical products in Switzerland, Europe, the United States, and internationally. It offers iron products, including Ferinject, Venofer, Maltofer, and Velphoro; Veltassa, a sodium-free potassium binder for the treatment of hyperkalaemia in adult patients; and Mircera, an erythropoiesis-stimulating agent for the treatment of symptomatic anemia associated with chronic kidney diseases. The company also provides infectious diseases/over-the-counter products, such as Broncho-Vaxom, an extract of various bacterial species for the treatment and prevention of recurrent respiratory infections; Uro-Vaxom, an extract of the bacterium Escherichia coli for the treatment and prevention of recurrent urinary tract infections; Dicynone for the prevention and treatment of capillary haemorrhages; Doxium for the oral treatment of diabetic retinopathy; and Aero-OM, an anti-flatulent for the oral treatment. Its development/pre-clinical products include VIT-2763, an oral ferroportin inhibitor, which is Phase I clinical trial for the treatment patients suffering from iron overload; Rayaldee for the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) and vitamin D deficiency; Biosimilar epoetin alfa the treatment of anemia associated with CKD, renal failure, and chemotherapy-induced anemia; Avacopan/CCX168, an orally administered inhibitor; CCX140, an orally administered inhibitor of the chemokine receptor; and Vadadustat, an oral investigational hypoxia-inducible factor stabiliser that is in Phase-III development for the treatment of anemia related to CKD. The company was formerly known as Galenica AG and changed its name to Vifor Pharma AG in April 2017. Vifor Pharma AG was founded in 1927 and is headquartered in St. Gallen, Switzerland.
Medicine Medical Specialties RTT Branches Of Biology Pharmaceutical Pharmaceutical Products Infectious Diseases Chemotherapy Chronic Kidney Disease Diabetic Retinopathy Anemia Chronic Kidney Diseases Organ Failure Erythropoiesis Stimulating Agent Secondary Hyperparathyroidism Acetic Acids Chemotherapy Induced Anemia Iron Overload Iron Products And Velphoro Development/Pre Clinical Products Galenica Including Ferinject Infectious Diseases/Over The Counter Products Maltofer Recurrent Respiratory Infections Recurrent Urinary Tract Infections Renal Failure Sucroferric Oxyhydroxide Symptomatic Anemia Treatment Of Secondary Hyperparathyroidism In Chronic Kidney Disease Vadadustat Velphoro Venofer Vifor Pharma Vit 2763 Vitamin D Deficiency

Is GNHAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News


Indicator Value
52 Week High 31.45
52 Week Low 24.4
Average Volume 3,777
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 25.7540
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.4459
MACD Signal Line 0.0892
MACD Histogram 0.3567
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.4500
Resistance 3 (R3) 31.4500 31.4500 31.4500
Resistance 2 (R2) 31.4500 31.4500 31.4500 31.4500
Resistance 1 (R1) 31.4500 31.4500 31.4500 31.4500 31.4500
Pivot Point 31.4500 31.4500 31.4500 31.4500 31.4500
Support 1 (S1) 31.4500 31.4500 31.4500 31.4500 31.4500
Support 2 (S2) 31.4500 31.4500 31.4500 31.4500
Support 3 (S3) 31.4500 31.4500 31.4500
Support 4 (S4) 31.4500